vs

Side-by-side financial comparison of Qudian Inc. (HTT) and INVO Fertility, Inc. (IVF). Click either name above to swap in a different company.

INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $1.1M, roughly 1.6× Qudian Inc.). Qudian Inc. runs the higher net margin — 239.8% vs -150.5%, a 390.3% gap on every dollar of revenue.

Qudian Inc. is a China-based fintech service provider that mainly offers small consumer credit solutions, risk management technical services, and related digital financial products. Its core target users are young mass consumers across China, with all key business operations focused on the domestic Chinese market.

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

HTT vs IVF — Head-to-Head

Bigger by revenue
IVF
IVF
1.6× larger
IVF
$1.8M
$1.1M
HTT
Higher net margin
HTT
HTT
390.3% more per $
HTT
239.8%
-150.5%
IVF

Income Statement — Q3 FY2024 vs Q3 FY2025

Metric
HTT
HTT
IVF
IVF
Revenue
$1.1M
$1.8M
Net Profit
$2.6M
$-2.6M
Gross Margin
11.1%
Operating Margin
-121.7%
-93.1%
Net Margin
239.8%
-150.5%
Revenue YoY
22.6%
Net Profit YoY
-62.2%
EPS (diluted)
$0.01
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HTT
HTT
IVF
IVF
Q3 25
$1.8M
Q2 25
$1.9M
Q1 25
$1.6M
Q4 24
$1.7M
Q3 24
$1.1M
$1.4M
Q2 24
$1.0M
$1.8M
Q1 24
$1.1M
$1.6M
Q4 23
$1.4M
Net Profit
HTT
HTT
IVF
IVF
Q3 25
$-2.6M
Q2 25
$-5.3M
Q1 25
$-17.4M
Q4 24
$-3.6M
Q3 24
$2.6M
$-1.6M
Q2 24
$1.9M
$-2.2M
Q1 24
$-1.4M
$-1.6M
Q4 23
$-2.0M
Gross Margin
HTT
HTT
IVF
IVF
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
11.1%
31.0%
Q2 24
13.3%
53.1%
Q1 24
45.3%
Q4 23
33.0%
Operating Margin
HTT
HTT
IVF
IVF
Q3 25
-93.1%
Q2 25
-160.4%
Q1 25
-1042.1%
Q4 24
-202.0%
Q3 24
-121.7%
-90.7%
Q2 24
-107.6%
-100.9%
Q1 24
-129.9%
-95.7%
Q4 23
-109.2%
Net Margin
HTT
HTT
IVF
IVF
Q3 25
-150.5%
Q2 25
-283.6%
Q1 25
-1060.1%
Q4 24
-211.3%
Q3 24
239.8%
-113.8%
Q2 24
187.1%
-122.2%
Q1 24
-131.8%
-101.3%
Q4 23
-144.4%
EPS (diluted)
HTT
HTT
IVF
IVF
Q3 25
$-0.77
Q2 25
$-13.30
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$0.01
$-15.11
Q2 24
$0.01
$-22.39
Q1 24
$-0.01
$-7.55
Q4 23
$-59.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HTT
HTT
IVF
IVF
Cash + ST InvestmentsLiquidity on hand
$104.9M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$225.2M
$5.8M
Total Assets
$246.8M
$18.8M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HTT
HTT
IVF
IVF
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$104.9M
Q2 24
$112.8M
Q1 24
$140.6M
Q4 23
Total Debt
HTT
HTT
IVF
IVF
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
HTT
HTT
IVF
IVF
Q3 25
$5.8M
Q2 25
$2.6M
Q1 25
$3.3M
Q4 24
$12.7M
Q3 24
$225.2M
$-23.3K
Q2 24
$217.5M
$1.4M
Q1 24
$218.9M
$10.2K
Q4 23
$892.8K
Total Assets
HTT
HTT
IVF
IVF
Q3 25
$18.8M
Q2 25
$19.3M
Q1 25
$31.7M
Q4 24
$46.4M
Q3 24
$246.8M
$17.0M
Q2 24
$227.9M
$17.8M
Q1 24
$234.9M
$17.3M
Q4 23
$18.5M
Debt / Equity
HTT
HTT
IVF
IVF
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HTT
HTT
IVF
IVF
Operating Cash FlowLast quarter
$-1.8M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HTT
HTT
IVF
IVF
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
Q2 24
$-1.5M
Q1 24
$-260.6K
Q4 23
$-714.9K
Free Cash Flow
HTT
HTT
IVF
IVF
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
Q4 23
FCF Margin
HTT
HTT
IVF
IVF
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Q4 23
Capex Intensity
HTT
HTT
IVF
IVF
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons